Evidence map›Paper›PMID 41385150›Full record

ArticleJournal of neuro-oncology2025

Brain metastases from renal cell carcinoma: a large retrospective claims-based oncology cohort analysis of prevalence, chronicity, and survival outcomes.

Megan Parker, Austin Carmichael, Alyssa G Arbuiso, Kelly Jiang, Joshua Materi, Debraj Mukherjee, David O Kamson, Kristin J Redmond, Lawrence R Kleinberg, Yasser Ged and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Megan ParkerDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Austin CarmichaelDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Alyssa G ArbuisoDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Kelly JiangDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Joshua MateriDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Debraj MukherjeeDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
David O KamsonDepartment of Neurology, Johns Hopkins Medicine, Baltimore, USA.
Kristin J RedmondDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, USA.
Lawrence R KleinbergDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, USA.
Yasser GedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA.
Nirmish SinglaThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University, Baltimore, USA.
Chetan BettegowdaDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA.
Jordina Rincon-TorroellaDepartment of Neurosurgery, Johns Hopkins Medicine, Baltimore, USA. jrincon2@jhmi.edu.ORCID http://orcid.org/0000-0003-4798-8231

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are few large population-based studies characterizing brain metastases (BM) in patients with renal cell carcinoma (RCC). The aim of this study was to investigate BM prevalence and their impact on treatment patterns and overall survival (OS) in RCC patients diagnosed between 2014 and 2024.

methodsData from patients with histologically confirmed RCC were extracted from the TriNetX Oncology database. Clinical and demographic variables were compared between patients with and without BM using Chi-squared and t-tests. Cox regression analyses were used to evaluate OS, after propensity score matching cohorts for age at diagnosis, sex, stage at diagnosis, cancer-directed therapy, and extracranial metastases.

resultsA total of 14,650 patients with RCC were identified, including 730 (5.0%) who developed BM. Patients with BM had higher rates of extracranial metastases and were more likely to receive radiation and antineoplastic medications than patients without BM. Patients with BM had significantly lower OS compared to those with extracranial metastases only (HR[95%CI] = 1.38[1.19–1.59]), with median survival times of 4.0 years from the diagnosis of RCC and 1.2 years from the BM diagnosis. From the time of diagnosis of RCC, patients with synchronous BM (diagnosed ≤ 2 months of RCC diagnosis) had poorer OS compared to patients with metachronous (diagnosed > 2 months of RCC diagnosis) BM (HR[95%CI] = 1.95[1.46–2.60]), but there was no significant difference in OS following the BM diagnosis between these groups (HR[95%CI] = 0.92[0.67–1.27]).

conclusionsHere we demonstrated the increased morbidity, mortality, and complexity in management associated with BM in patients with RCC, regardless of their chronicity.

Indexed as

Brain NeoplasmsCarcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrevalencePrognosisRetrospective StudiesSurvival RateBrain metastasesRenal cell carcinomaTriNetX

Identifiers

PMID41385150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.